Interagency Patent Coordination and Improvement Act of 2025 This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products. The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the USPTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the USPTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the USPTO, and (3) the USPTO to assist the FDA in its ministerial role of listing patents.
Have questions about this legislation?
Our AI can explain provisions, analyze impacts, and answer questions in plain English.
Already have an account? Sign in
Make your voice heard on this bill.
Upgrade to Plus to generate an AI letter and send it to your House representative.
Get an instant AI-powered breakdown of this bill — what it does, who it affects, and what matters.
Create free accountAlready have an account? Sign in
Hear what historical figures and modern thinkers might say about this legislation.
Founding Fathers
Historical Leaders
Modern Thinkers
See how Jefferson, Churchill, or Einstein would react to this bill.
Create free accountAlready have an account? Sign in